Indivior Pharmaceuticals Inc.
INDV Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS grew 580.0%, free cash flow grew 58.6% and total debt rose 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow INDV
Indivior Pharmaceuticals Inc. (INDV) P/E ratio
As of 16 October 2026, Indivior Pharmaceuticals Inc. (INDV) trades at a P/E ratio of 11.2×. Over the past ten years it has ranged from 0.0× (June 2025) to 92.0× (February 2017); the current reading is higher than 52% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 19.2× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 21.2× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 12.3× | — |
| FY2020 | 0.0× | — |
| FY2019 | 2.9× | (18.68%) |
| FY2018 | 3.6× | (94.83%) |
| FY2017 | 68.8× | (3.17%) |
| FY2016 | 71.0× | 727.88% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 14.2× | (5.91%) |
| Mar 2026 | 15.1× | (28.93%) |
| Dec 2025 | 21.2× | (9.62%) |
| Sep 2025 | 23.5× | 35.95% |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AMLX Amylyx Pharmaceuticals, Inc. compare | n/m |
| RGC Regencell Bioscience Holdings Limited compare | n/m |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | n/m |
| INDV Indivior Pharmaceuticals Inc. | 11.2× |
| LQDA Liquidia Corporation compare | 21.9× |
| LNTH Lantheus Holdings, Inc. compare | 23.7× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 38.4× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 73.4× |
| ALKS Alkermes plc compare | 102× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)